Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Change in Accured Expenses (2020 - 2025)

Historic Change in Accured Expenses for Bioventus (BVS) over the last 6 years, with Q3 2025 value amounting to $7.3 million.

  • Bioventus' Change in Accured Expenses rose 13427.89% to $7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 8215.51%. This contributed to the annual value of $17.8 million for FY2024, which is 43831.28% up from last year.
  • As of Q3 2025, Bioventus' Change in Accured Expenses stood at $7.3 million, which was up 13427.89% from $16.4 million recorded in Q2 2025.
  • Over the past 5 years, Bioventus' Change in Accured Expenses peaked at $29.9 million during Q2 2024, and registered a low of -$39.1 million during Q1 2025.
  • In the last 5 years, Bioventus' Change in Accured Expenses had a median value of $5.8 million in 2023 and averaged $648052.6.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first soared by 86222.52% in 2021, then plummeted by 91194.0% in 2022.
  • Over the past 5 years, Bioventus' Change in Accured Expenses (Quarter) stood at $11.0 million in 2021, then skyrocketed by 30.53% to $14.3 million in 2022, then tumbled by 59.53% to $5.8 million in 2023, then surged by 186.98% to $16.6 million in 2024, then crashed by 56.02% to $7.3 million in 2025.
  • Its Change in Accured Expenses was $7.3 million in Q3 2025, compared to $16.4 million in Q2 2025 and -$39.1 million in Q1 2025.